sST2 Protein Serum Levels in Patients with Chronic Heart Failure

ORIGINAL ARTICLE
Roman E. Tokmachev, Andrey Ya. Kravchenko, Andrey V. Budnevsky, Evgeniy S. Ovsyannikov, Tatiana A. Chernik, Evgeny V. Tokmachev, Yanina S. Shkatova

 
International Journal of Biomedicine. 2020;10(4):342-346.
DOI: 10.21103/Article10(4)_OA2
Originally published December 10, 2020

Abstract: 

The purpose of this study was to determine the blood concentration of sST2 and evaluate the correlations between sST2 and the clinical, instrumental, and echocardiographic characteristics of patients with CHFrEF (chronic heart failure with reduced ejection fraction) and CHFpEF (chronic heart failure with preserved ejection fraction), as well as to evaluate the sST2 informativeness in comparison with NT-proBNP.
The study involved 160 patients diagnosed with CHF (86 men and 74 women, mean age of 72.4±8.7 years). According to the LVEF value, the patients were divided into two groups: CHFpEF (EF≥50%) was recorded in 69 people, CHFrEF (EF<50%) - in 91 people. The functional class (FC) of CHF was determined according to the NYHA classification (1994). NT-proBNP and hs-CRP levels had a stronger positive association with sST2 levels in CHFrEF patients than in CHFpEF patients. The results obtained (regardless of the EF) indicated a statistically significant direct correlation between the levels of sST2 and LAVI. The weak direct correlation between sST2 and NYHA FC, in contrast to the direct strong correlation between NT-proBNP and sST2, indicates that sST2, which is quite important both for determining the current state of the patient and for predicting the course of the disease, still cannot be used as a single and universal indicator. In this regard, further comprehensive study of the diagnostic and prognostic capabilities of the sST2 and NT-proBNP biomarkers in CHF patients with different EF is required.

Keywords: 
sST2 • NT-proBNP • hs-CRP • CHFrEF • CHFpEF
References: 
  1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016 Aug;18(8):891-975. doi: 10.1002/ejhf.592.
  2. Budnevsky AV, Shurupova AD, Kravchenko AY, Tokmachev RE. Clinical efficacy of acute respiratory viral infections prevention in patients with chronic heart failure. Ter Arkh. 2019 Mar 30;91(3):36-41. doi: 10.26442/00403660.2019.03.000111.  [Article in Russian].
  3. Tokmachev RE, Kravchenko AYa, Budnevsky AV, et al. Activation of pro-inflammatory cytokines in patients with chronic heart failure comorbid with metabolic syndrome. Kardiovaskulyarnaya Trapiya i Profilaktika. 2015;14(2):116-117. [Article in Russian].
  4. Burnett H, Earley A, Voors AA, Senni M, McMurray JJ, Deschaseaux C, Cope S. Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-Analysis. Circ Heart Fail. 2017 Jan;10(1):e003529. doi: 10.1161/CIRCHEARTFAILURE.116.003529.
  5. Tschöpe C, Birner C, Böhm M, Bruder O, Frantz S, Luchner A, Maier L, Störk S, Kherad B, Laufs U. Heart failure with preserved ejection fraction: current management and future strategies : Expert opinion on the behalf of the Nucleus of the "Heart Failure Working Group" of the German Society of Cardiology (DKG). Clin Res Cardiol. 2018 Jan;107(1):1-19. doi: 10.1007/s00392-017-1170-6. 
  6. Chen YT, Wong LL, Liew OW, Richards AM. Heart Failure with Reduced Ejection Fraction (HFrEF) and Preserved Ejection Fraction (HFpEF): The Diagnostic Value of Circulating MicroRNAs. Cells. 2019 Dec 16;8(12):1651. doi: 10.3390/cells8121651. 
  7. Bielecka-Dabrowa A, Gluba-Brzózka A, Michalska-Kasiczak M, Misztal M, Rysz J, Banach M. The multi-biomarker approach for heart failure in patients with hypertension. Int J Mol Sci. 2015 May 12;16(5):10715-33. doi: 10.3390/ijms160510715
  8. Werenskiold AK, Hoffmann S, Klemenz R. Induction of a mitogen-responsive gene after expression of the Ha-ras oncogene in NIH 3T3 fibroblasts. Mol Cell Biol. 1989 Nov;9(11):5207-14. doi: 10.1128/mcb.9.11.5207. 
  9. Tominaga S. A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett. 1989 Dec 4;258(2):301-4. doi: 10.1016/0014-5793(89)81679-5. 
  10. Andreasová T, Vránová J, Vondráková D, Sedláčková L, Zákostelská ZJ, Neužil P, Málek F. Role of biomarkers of cardiac remodeling, myofibrosis, and inflammation in assessment of disease severity in euvolemic patients with chronic stable heart failure. J Int Med Res. 2020 Aug;48(8):300060520947869. doi: 10.1177/0300060520947869. 
  11. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, Gorman DM, Bazan JF, Kastelein RA. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005 Nov;23(5):479-90. doi: 10.1016/j.immuni.2005.09.015. 
  12. Liew FY, Girard JP, Turnquist HR. Interleukin-33 in health and disease. Nat Rev Immunol. 2016 Nov;16(11):676-689. doi: 10.1038/nri.2016.95.
  13. Pascual-Figal DA, Januzzi JL. The biology of ST2: the International ST2 Consensus Panel. Am J Cardiol. 2015 Apr 2;115(7 Suppl):3B-7B. doi: 10.1016/j.amjcard.2015.01.034. 
  14. Villacorta H, Maisel AS. Soluble ST2 Testing: A Promising Biomarker in the Management of Heart Failure. Arq Bras Cardiol. 2016 Feb;106(2):145-52. doi: 10.5935/abc.20150151.
  15. Kuster N, Huet F, Dupuy AM, Akodad M, Battistella P, Agullo A, Leclercq F, Kalmanovich E, Meilhac A, Aguilhon S, Cristol JP, Roubille F. Multimarker approach including CRP, sST2 and GDF-15 for prognostic stratification in stable heart failure. ESC Heart Fail. 2020 Jul 10;7(5):2230–9. doi: 10.1002/ehf2.12680. 
  16. Bayes-Genis A, Zhang Y, Ky B. ST2 and patient prognosis in chronic heart failure. Am J Cardiol. 2015 Apr 2;115(7 Suppl):64B-9B. doi: 10.1016/j.amjcard.2015.01.043.
  17. Tromp J, Westenbrink BD, Ouwerkerk W, van Veldhuisen DJ, Samani NJ, Ponikowski P, Metra M, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Lang CC, Ng LL, Zannad F, Zwinderman AH, Hillege HL, van der Meer P, Voors AA. Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction. J Am Coll Cardiol. 2018 Sep 4;72(10):1081-1090. doi: 10.1016/j.jacc.2018.06.050. 
  18. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989 Sep-Oct;2(5):358-67. doi: 10.1016/s0894-7317(89)80014-8. 
  19. Santos AB, Kraigher-Krainer E, Gupta DK, Claggett B, Zile MR, Pieske B, Voors AA, Lefkowitz M, Bransford T, Shi V, Packer M, McMurray JJ, Shah AM, Solomon SD; PARAMOUNT Investigators. Impaired left atrial function in heart failure with preserved ejection fraction. Eur J Heart Fail. 2014 Oct;16(10):1096-103. doi: 10.1002/ejhf.147.
  20. Hartmann F, Packer M, Coats AJ, Fowler MB, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Anker SD, Amann-Zalan I, Hoersch S, Katus HA. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation. 2004 Sep 28;110(13):1780-6. doi: 10.1161/01.CIR.0000143059.68996.A7. 
  21. Olsson LG, Swedberg K, Cleland JG, Spark PA, Komajda M, Metra M, Torp-Pedersen C, Remme WJ, Scherhag A, Poole-Wilson P; COMET Investigators. Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trial. Eur J Heart Fail. 2007 Aug;9(8):795-801. doi: 10.1016/j.ejheart.2007.07.010. 
  22. Cleland JG, McMurray JJ, Kjekshus J, Cornel JH, Dunselman P, Fonseca C, Hjalmarson A, Korewicki J, Lindberg M, Ranjith N, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J; CORONA Study Group. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol. 2009 Nov 10;54(20):1850-9. doi: 10.1016/j.jacc.2009.06.041.
  23. Valle R, Aspromonte N, Feola M, Milli M, Canali C, Giovinazzo P, Carbonieri E, Ceci V, Cerisano S, Barro S, Milani L. B-type natriuretic peptide can predict the medium-term risk in patients with acute heart failure and preserved systolic function. J Card Fail. 2005 Sep;11(7):498-503. doi: 10.1016/j.cardfail.2005.05.002.
  24. Anand IS, Rector TS, Cleland JG, Kuskowski M, McKelvie RS, Persson H, McMurray JJ, Zile MR, Komajda M, Massie BM, Carson PE. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail. 2011 Sep;4(5):569-77. doi: 10.1161/CIRCHEARTFAILURE.111.962654.
  25. Yan J, Gong SJ, Li L, Yu HY, Dai HW, Chen J, Tan CW, Xv QH, Cai GL. Combination of B-type natriuretic peptide and minute ventilation/carbon dioxide production slope improves risk stratification in patients with diastolic heart failure. Int J Cardiol. 2013 Jan 20;162(3):193-8. doi: 10.1016/j.ijcard.2011.07.017.
  26. Santema BT, Chan MMY, Tromp J, Dokter M, van der Wal HH, Emmens JE, Takens J, Samani NJ, Ng LL, Lang CC, van der Meer P, Ter Maaten JM, Damman K, Dickstein K, Cleland JG, Zannad F, Anker SD, Metra M, van der Harst P, de Boer RA, van Veldhuisen DJ, Rienstra M, Lam CSP, Voors AA. The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure. Clin Res Cardiol. 2020 Mar;109(3):331-338. doi: 10.1007/s00392-019-01513-y. 
  27. Xanthakis V, Larson MG, Wollert KC, Aragam J, Cheng S, Ho J, Coglianese E, Levy D, Colucci WS, Michael Felker G, Benjamin EJ, Januzzi JL, Wang TJ, Vasan RS. Association of novel biomarkers of cardiovascular stress with left ventricular hypertrophy and dysfunction: implications for screening. J Am Heart Assoc. 2013 Nov 7;2(6):e000399. doi: 10.1161/JAHA.113.000399.

Download Article
Received September 18, 2020.
Accepted October 24, 2020.
©2020 International Medical Research and Development Corporation.